Instituto de Bioquímica Aplicada, Facultad de Bioquímica, Química y Farmacia, Universidad Nacional de Tucumán, Balcarce 747, CP 4000, San Miguel de Tucumán, Tucumán, Argentina.
J Inflamm (Lond). 2009 Oct 16;6:28. doi: 10.1186/1476-9255-6-28.
We have previously demonstrated that Lactobacillus casei CRL 431 administration improved the resistance to pneumococcal infection in a mouse model.
This study examined the effects of the oral administration of Lactobacillus casei CRL 431 (L. casei) on the activation of coagulation and fibrinolytic systems as well as their inhibitors during a Streptococcus pneumoniae infection in mice.
The alveolo-capillary membrane was damaged and the coagulation system was also activated by the infection. As a consequence, we could see fibrin(ogen) deposits in lung histological slices, increased levels of thrombin-antithrombin complex (TATc) in bronchoalveolar lavage (BAL) and plasma, decrease in prothrombin activity (PT) and prolonged activated partial thromboplastin time test (APTT) values. Factor VII (FVII) and factor X (FX) were decreased in plasma, whereas fibrinogen (F) and factor VIII (FVIII) were increased. The low levels of protein C (PC) in BAL and plasma proved damage on inhibitory activity. The infected animals showed reduced fibrinolytic activity, evidenced by an increase in plasminogen activation inhibitor-1 (PAI-1) in BAL and plasma. The pathogen induced an increase of TNF-alpha, IL-1beta and IL-6 in BAL and serum a few hours after challenge followed by a significant decrease until the end of the assayed period. IL-4 and IL-10 in BAL and serum were also augmented, especially at the end of the experiment. The animals treated with L. casei showed an improvement of alveolo-capillary membrane, lower fibrin(ogen) deposits in lung and decrease in TATc. APTT test and PT, FVII and FX activity were normalized. L. casei group showed lower F levels than control during whole experiment. In the present study no effect of L. casei on the recovery of the inhibitory activity was detected. However, L. casei was effective in reducing PAI-1 levels in BAL and in increasing anti-inflammatory ILs concentration.
L. casei proved effective to regulate coagulation activation and fibrinolysis inhibition during infection, leading to a decrease in fibrin deposits in lung. This protective effect of L. casei would be mediated by the induction of higher levels of IL-4 and IL-10 which could regulate the anti-inflammatory, procoagulant and antifibrinolytic effects of TNF-alpha, IL-1beta and IL-6.
我们之前的研究表明,干酪乳杆菌 CRL431 的给药可提高小鼠肺炎球菌感染的抵抗力。
本研究检查了干酪乳杆菌 CRL431(L. casei)口服给药对肺炎链球菌感染期间凝血和纤维蛋白溶解系统及其抑制剂激活的影响。
肺泡毛细血管膜被感染破坏,凝血系统也被激活。因此,我们可以在肺组织切片中看到纤维蛋白(原)沉积,支气管肺泡灌洗液(BAL)和血浆中凝血酶-抗凝血酶复合物(TATc)水平升高,凝血酶原活性(PT)降低,活化部分凝血活酶时间试验(APTT)值延长。血浆中因子 VII(FVII)和因子 X(FX)降低,而纤维蛋白原(F)和因子 VIII(FVIII)升高。BAL 和血浆中蛋白 C(PC)水平降低证明了抑制活性的损伤。感染动物的纤维蛋白溶解活性降低,BAL 和血浆中纤溶酶原激活物抑制剂-1(PAI-1)增加证明了这一点。病原体在挑战后数小时内在 BAL 和血清中诱导 TNF-α、IL-1β 和 IL-6 的增加,随后在整个检测期结束时显著降低。BAL 和血清中的 IL-4 和 IL-10 也增加,尤其是在实验结束时。用 L. casei 治疗的动物显示肺泡毛细血管膜改善,肺中纤维蛋白(原)沉积减少,TATc 降低。APTT 试验和 PT、FVII 和 FX 活性恢复正常。L. casei 组在整个实验过程中的 F 水平均低于对照组。在本研究中,未发现 L. casei 对抑制活性的恢复有影响。然而,L. casei 有效降低 BAL 中的 PAI-1 水平,并增加抗炎性 IL 的浓度。
L. casei 在感染期间对凝血激活和纤维蛋白溶解抑制的调节有效,导致肺中纤维蛋白沉积减少。L. casei 的这种保护作用可能是通过诱导更高水平的 IL-4 和 IL-10 介导的,这些细胞因子可以调节 TNF-α、IL-1β 和 IL-6 的抗炎、促凝和抗纤维蛋白溶解作用。